Key facts
- It has raised $11.0M; the latest was Early Stage VC ($11.0M) in Mar 2026.
- Notable investors include Caffeinated Capital, Clocktower Ventures, Haystack Management Company, Hawktail, Basis Set Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Neion Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Neion Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neion Bio
Developer of a biomanufacturing platform designed to produce biological medicines using re-engineered protein systems. The company offers genetically engineered egg-based bioreactors and advanced genome engineering techniques, enabling biopharmaceutical and animal health companies to manufacture biological molecules with improved scalability, consistency, and cost efficiency.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 13
- Website
- neionbio.com/
- Ownership
- Privately Held (backing)
Neion Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neion Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neion Bio in its N-PORT filings yet. We sweep new filings monthly.